For the year ending 2025-12-31, ORKA had -$14,640K decrease in cash & cash equivalents over the period. -$88,419K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -105,433 |
| Stock-based compensation expense | 24,240 |
| Net accretion of premiums and discounts on marketable securities | 5,003 |
| Non-cash lease expense | 458 |
| Depreciation expense | 83 |
| Prepaid expenses and other current assets | 3,972 |
| Other non-current assets | 60 |
| Accounts payable | 693 |
| Accrued expenses and other current liabilities | 7,245 |
| Operating lease liability | -448 |
| Related party accounts payable and other current liabilities | -6,013 |
| Net cash used in operating activities | -88,210 |
| Purchases of property and equipment | 209 |
| Purchases of marketable securities | 520,959 |
| Proceeds from maturities of marketable securities | 424,423 |
| Net cash used in investing activities | -96,745 |
| Proceeds from the pipe financings, net | 169,644 |
| Proceeds from issuance of common stock upon exercise of stock options and employee warrants and purchases under employee stock purchase plan | 671 |
| Net cash provided by financing activities | 170,315 |
| Net (decrease) increase in cash and cash equivalents | -14,640 |
| Cash and cash equivalents at beginning of period | 61,575 |
| Cash and cash equivalents at end of period | 46,935 |
Oruka Therapeutics, Inc. (ORKA)
Oruka Therapeutics, Inc. (ORKA)